Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Monteverde & Associates PC Announces an Investigation of Immunomedics, Inc. - IMMU

share with twitter share with LinkedIn share with facebook
09/18/2020 | 08:01pm EDT

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Immunomedics, Inc. ("Immunomedics" or the "Company") (IMMU) relating to the sale of the Company to Gilead Sciences, Inc. Under the terms of the agreement, Immunomedics shareholders are anticipated to receive $88.00 per share for each share of Immunomedics they own.

Click here for more information: https://www.monteverdelaw.com/case/immunomedics-inc. It is free and there is no cost or obligation to you.

The investigation focuses on whether Immunomedics and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company's stockholders by 1) failing to conduct a fair process, 2) whether and by how much this proposed transaction undervalues the Company and 3) failing to disclose all material information.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing.  Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions.  Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field.  He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer.  Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019).  Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in Immunomedics, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:
Juan E. Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4405
New York, NY 10118
United States of America
jmonteverde@monteverdelaw.com
Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com).  Prior results do not guarantee a similar outcome with respect to any future matter.

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-immunomedics-inc--immu-301134120.html

SOURCE Monteverde & Associates PC

© PRNewswire 2020

share with twitter share with LinkedIn share with facebook
Latest news "Companies"
06:15aHOME DEPOT : Won a Lot of Customers During the Pandemic. The Trick Is Keeping Them. -- Journal Report
DJ
05:48aBASEBALL : Pacific League standings (Oct. 24)
AQ
04:36aAILERON THERAPEUTICS : Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
AQ
04:36aAileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
GL
03:35aSGT GERMAN PRIVATE EQUITY GMBH & CO. KGAA : Notification and public disclosure of transactions by persons
EQ
03:30aSGT GERMAN PRIVATE EQUITY GMBH & CO. KGAA : Notification and public disclosure of transactions by persons
EQ
03:08aPACIFIC GAS & ELECTRIC : PG&E may cut power to over 1 million people in California
AQ
03:01aEVE INVESTMENTS : Private Placement Markets to Expand Its Alternative Energy Operations
AQ
03:01aINNOVATION : Decentralized Innovation Inc. (d10i) Joins the InterWork Alliance
AQ
02:55aREPLACE - EXTRAORDINARY/ SPECIAL GENERAL MEETING : : Voluntary
PU
Latest news "Companies"